Abstract
Chiral amines are valuable building blocks for the pharmaceutical industry. ω-TAms have emerged as an exciting option for their synthesis, offering a potential "green alternative" to overcome the drawbacks associated with conventional chemical methods. In this review, we explore the application of ω-TAms for pharmaceutical production. We discuss the diverse array of reactions available involving ω-TAms and process considerations of their use in both kinetic resolution and asymmetric synthesis. With the aid of specific drug intermediates and APIs, we chart the development of ω-TAms using protein engineering and their contribution to elegant one-pot cascades with other enzymes, including carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive overview of their uses, beginning with initial applications through to the present day.
Language | English |
---|---|
Pages | 349-367 |
Number of pages | 19 |
Journal | Chemical Reviews |
Volume | 118 |
Issue number | 1 |
DOIs | |
Publication status | Published - 10 Jan 2018 |
Fingerprint
Keywords
- Alcohol Oxidoreductases/chemistry
- Amines/metabolism
- Biocatalysis
- Drug Industry
- Monoamine Oxidase/chemistry
- Protein Engineering
- Stereoisomerism
- Transaminases/chemistry
Cite this
}
Application of ω-Transaminases in the Pharmaceutical Industry. / Kelly, Stephen A.; Pohle, Stefan; Wharry, Scott; Mix, Stefan; Allen, Christopher C.R.; Moody, Thomas S.; Gilmore, Brendan F.
In: Chemical Reviews, Vol. 118, No. 1, 10.01.2018, p. 349-367.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Application of ω-Transaminases in the Pharmaceutical Industry
AU - Kelly, Stephen A.
AU - Pohle, Stefan
AU - Wharry, Scott
AU - Mix, Stefan
AU - Allen, Christopher C.R.
AU - Moody, Thomas S.
AU - Gilmore, Brendan F.
PY - 2018/1/10
Y1 - 2018/1/10
N2 - Chiral amines are valuable building blocks for the pharmaceutical industry. ω-TAms have emerged as an exciting option for their synthesis, offering a potential "green alternative" to overcome the drawbacks associated with conventional chemical methods. In this review, we explore the application of ω-TAms for pharmaceutical production. We discuss the diverse array of reactions available involving ω-TAms and process considerations of their use in both kinetic resolution and asymmetric synthesis. With the aid of specific drug intermediates and APIs, we chart the development of ω-TAms using protein engineering and their contribution to elegant one-pot cascades with other enzymes, including carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive overview of their uses, beginning with initial applications through to the present day.
AB - Chiral amines are valuable building blocks for the pharmaceutical industry. ω-TAms have emerged as an exciting option for their synthesis, offering a potential "green alternative" to overcome the drawbacks associated with conventional chemical methods. In this review, we explore the application of ω-TAms for pharmaceutical production. We discuss the diverse array of reactions available involving ω-TAms and process considerations of their use in both kinetic resolution and asymmetric synthesis. With the aid of specific drug intermediates and APIs, we chart the development of ω-TAms using protein engineering and their contribution to elegant one-pot cascades with other enzymes, including carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive overview of their uses, beginning with initial applications through to the present day.
KW - Alcohol Oxidoreductases/chemistry
KW - Amines/metabolism
KW - Biocatalysis
KW - Drug Industry
KW - Monoamine Oxidase/chemistry
KW - Protein Engineering
KW - Stereoisomerism
KW - Transaminases/chemistry
UR - http://www.scopus.com/inward/record.url?scp=85040313825&partnerID=8YFLogxK
U2 - 10.1021/acs.chemrev.7b00437
DO - 10.1021/acs.chemrev.7b00437
M3 - Review article
VL - 118
SP - 349
EP - 367
JO - Chemical Reviews
T2 - Chemical Reviews
JF - Chemical Reviews
SN - 0009-2665
IS - 1
ER -